Wall Street analysts expect that Proteostasis Therapeutics Inc (NASDAQ:PTI) will post ($0.29) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Proteostasis Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.26) and the lowest estimate coming in at ($0.31). Proteostasis Therapeutics posted earnings per share of ($0.36) during the same quarter last year, which indicates a positive year-over-year growth rate of 19.4%. The company is expected to issue its next earnings results on Friday, March 13th.

On average, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($1.20) per share for the current year, with EPS estimates ranging from ($1.23) to ($1.18). For the next fiscal year, analysts expect that the firm will post earnings of ($1.28) per share, with EPS estimates ranging from ($1.61) to ($1.11). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Proteostasis Therapeutics.

Proteostasis Therapeutics (NASDAQ:PTI) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.15.

PTI has been the topic of a number of research analyst reports. ValuEngine raised Proteostasis Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Piper Jaffray Companies restated a “buy” rating and set a $4.00 price objective on shares of Proteostasis Therapeutics in a research report on Tuesday, December 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Proteostasis Therapeutics in a research note on Friday, October 18th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Proteostasis Therapeutics in a research note on Monday, December 23rd. Finally, Zacks Investment Research raised Proteostasis Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a report on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $6.75.

NASDAQ:PTI opened at $1.94 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.89 and a quick ratio of 6.89. The business has a 50 day simple moving average of $2.55 and a 200 day simple moving average of $1.30. The firm has a market capitalization of $96.63 million, a P/E ratio of -1.20 and a beta of 0.29. Proteostasis Therapeutics has a 12-month low of $0.61 and a 12-month high of $4.72.

In other news, major shareholder Enterprise Associates 12 New sold 117,164 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $2.45, for a total value of $287,051.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 19.80% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC lifted its position in shares of Proteostasis Therapeutics by 62.4% in the 3rd quarter. Squarepoint Ops LLC now owns 44,569 shares of the company’s stock worth $38,000 after acquiring an additional 17,120 shares during the period. Paloma Partners Management Co acquired a new position in Proteostasis Therapeutics in the second quarter valued at about $150,000. Jane Street Group LLC grew its stake in Proteostasis Therapeutics by 445.5% during the second quarter. Jane Street Group LLC now owns 175,050 shares of the company’s stock worth $171,000 after buying an additional 142,958 shares during the last quarter. Finally, A.R.T. Advisors LLC acquired a new position in shares of Proteostasis Therapeutics in the 2nd quarter worth approximately $189,000. Institutional investors own 41.49% of the company’s stock.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.

Recommended Story: Closed-End Mutual Funds

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.